Nitrogen-containing
bisphosphonates (NBPs), anti-bone-resorptive drugs, exhibit inflammatory side effects (
fever, jaw
osteomyelitis or
osteonecrosis, etc.). We previously reported that in mice: (i) a single
intraperitoneal injection of
alendronate (an NBP, 40 μmol/kg or less) induces various inflammatory reactions, (ii) these effects, which are minimal in IL-1-deficient mice, can be prevented by co-administration of
clodronate (a non-NBP, 40 μmol/kg or less), and (iii)
alendronate increases IL-1β in tissues (liver, spleen, and lung), but strangely not in blood. Here, we found the following in mice. (a) The IL-1β in tissues is pro-IL-1β. (b) Unlike LPS,
alendronate induces minimal activation of caspase-1 (pro-IL-1β-processing enzyme). (c) The tissue pro-IL-1β elevations are largely absent in macrophage-depleted mice. (d) In vitro, 100 μM
alendronate directly stimulates RAW 264 cells (murine macrophage-like cells) to produce pro-IL-1β, and 1 μM
clodronate inhibits this effect. These results suggest that in mice: (i) the major pro-IL-1β-producing cells in response to
alendronate are macrophages, (ii)
alendronate directly stimulates them to produce pro-IL-1β, but the release of mature IL-1β is below detectable levels due to insufficient activation of caspase-1, and (iii)
clodronate inhibits the pro-IL-1β production by acting directly on macrophages, although the in vivo mechanism may differ from the in vitro one.